At the point-of-care, Celution One extracts and concentrates patient’s own stem and progenitor cells from adipose (fat) tissue.
The company said the Celution One, which is used in hospitals, improves greater cell yield, greater range of processing volumes and faster processing times, increases the versatility and efficiencies of potential treatments.
Cytori CEO Christopher Calhoun said they are also using the Celution One in their pivotal heart attack trial, Advance, with the goal of seeking expanded market access through broader indications-for-use and subsequent reimbursement applications.
